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Rho GTPases are master regulators of cell shape and cell movement [1].  The archetypal family 
members RhoA, Rac1 and Cdc42 arose early in eukaryotic evolution and coordinate a diverse 
range of cell morphologies and migrations.  Evolution of the vertebrates was paralleled by 
expansion of this family through gene duplication.  Emergence of an adaptive immune system 
and more complex neural systems presented new roles for Rho GTPases, filled by new family 
members.  Cdc42 underwent gene duplication to produce two related proteins – RhoQ and 
RhoJ [2].  RhoQ is active in neural dynamics; however, RhoJ is highly expressed in endothelial 
cells under control of the endothelial-specific promoter ERG [3, 4].  RhoJ is required for 
angiogenesis [5, 6] and has multiple roles in this process [7, 8].  We recently demonstrated that 
RhoJ regulates the endosomal trafficking of podocalyxin during angiogenesis to control lumen 
formation [9].  Here we use vesicle purification and proteomic analysis to identify the endothelial 
targets of RhoJ-mediated trafficking.  We identify α5β1 integrin as a major RhoJ cargo and 
show that RhoJ regulates the intracellular trafficking of active α5β1 integrin in endothelial cells 
to repress fibronectin fibrillogenesis.  Accordingly, mice lacking RhoJ show deregulated 
deposition of fibronectin around vessels during developmental angiogenesis.  Intriguingly, we 
show that RhoJ acts in opposition to Cdc42 in this process through competition for a shared 
partner, PAK3.  These studies identify a critical role for RhoJ in matrix remodeling during blood 












RESULTS AND DISCUSSION 
 
Endothelial RhoJ+ vesicles transport α5β1 integrin 
Cdc42 and RhoJ are both required for angiogenesis [5, 10], suggesting that these related 
proteins have discrete functions in the process.  The most immediately apparent difference 
between the two is in their localization.  In primary human endothelial cells (ECs) we observed a 
broad cytoplasmic distribution for Cdc42, whereas RhoJ also localized to a vesicular pool 
(Figure 1A).  RhoJ was first identified as an endosomal Rho GTPase [11], and accordingly 
these vesicles colocalized with the early endosomal marker EEA1 and the late 
endosomal/lysosomal marker LAMP1 (Figures 1A, S1A).  We purified these vesicles to 
determine their content.  Primary ECs were transduced with GFP-tagged RhoJ and the cells 
broken mechanically.  Cellular membranes were fractionated by centrifugation on iodixanol 
density gradients.  RhoJ was detected in plasma membrane fractions and in the early and late 
endosomal fractions (Figure 1B).  We pooled the vesicular RhoJ fractions and further purified 
these by particle sorting.  The membrane fractions were incubated with Calcein Violet to label 
sealed vesicles [12] and dual-sorted to derive a homogenous GFP-RhoJ+ vesicle population 
(Figure 1C).  The protein content was then determined by mass spectrometry.  In keeping with 
their identity, RhoJ+ vesicles were marked by a subset of endosomal Rab GTPases (Figure 1D, 
Data S1).  Intriguingly, the cargo of RhoJ+ vesicles was enriched in cell adhesion proteins, 
including both integrins, EC adhesion molecules and also desmosome components (Figure 1D; 
Data S1).  The most abundant integrin was α5β1, which is required for both normal 
developmental angiogenesis and for tumor angiogenesis [13, 14].  Staining of ECs for 
endogenous α5 and β1 integrin subunits revealed strong colocalization with RhoJ+ vesicles 
(Figure 1E).  The colocalization with α5 was greater than with β1 (78% versus 52%; Figure 1E).  
β1 integrin is part of multiple integrin dimers in ECs, whereas α5 is only found in the α5β1 
complex [15].  We examined the localization of three other adhesion proteins from the RhoJ 
vesicle proteome – PECAM, VE-cadherin and α2 integrin (Figure S1B).  All showed 
colocalization with RhoJ in vesicles, although to a lesser degree than α5β1 integrin (Figure 
S1B).  We conclude that α5β1 integrin is a major cargo of RhoJ+ vesicles in ECs. 
 
RhoJ regulates trafficking of active endothelial α5β1 integrin 
Integrin trafficking is critical to integrin function.  Integrins from disassembled adhesions must be 
endocytosed and then recycled to new adhesive sites to allow for dynamic morphology and 
migration [16, 17].  We were interested to see if RhoJ regulated α5β1 trafficking.  As α5 is only 
found in the α5β1 complex [15], we examined α5 localization as a surrogate for α5β1 integrin.  
Silencing of RhoJ (Figure 2A) had no effect on the cellular distribution of total α5 integrin, as 
judged by immunofluorescence microscopy (Figure 2B), or density gradient fractionation (Figure 
S2A).  Similarly, expression of an activated RhoJ-QL mutant had no apparent effect on the 
distribution of total α5 integrin (Figures 2B, S2C).  The SNAKA51 antibody is specific for the 
extended conformation of the α5β1 complex [18] and consequently recognizes α5β1 in its 
activated form in fibrillar adhesions [19].  Silencing of RhoJ significantly increased SNAKA51 
staining in ECs, consistent with an increase in activation of α5β1 integrin (Figure 2C).  In 
contrast, expression of activated RhoJ significantly reduced SNAKA51 staining (Figure 2C).  We 
isolated α5β1 from ECs by immunoprecipitation with either total α5 integrin antibody or 
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SNAKA51.  Silencing of RhoJ had no effect on total levels of α5β1 (Figure S2B), but 
significantly increased the proportion of activated integrin (Figure 2D).  Conversely, activated 
RhoJ dramatically reduced levels of activated α5β1 (Figure 2E), without affecting total α5β1 
levels (Figure S2C).   
 
Silencing of RhoJ increased SNAKA51 staining at fibrillar adhesions and also seemingly in 
vesicles (Figure 2C).  We found that permeabilization of ECs with saponin allowed selective 
visualization of the vesicular pool, facilitating its quantification.  RhoJ silencing significantly 
increased the number of SNAKA51+ vesicles (Figure S2D), suggesting increased uptake of the 
activated integrin.  We examined this using an internalization assay.  Surface proteins were 
biotinylated on ice and then allowed to internalize following a shift to 37°C.  At each time point, 
cells were treated to remove surface biotinylation and the remaining (internalized) biotinylated 
protein was captured.  Levels of internalized α5β1 were quantified by ELISA.  Silencing of RhoJ 
had no significant effect on the endocytosis of total α5β1 (Figure 2F) in keeping with the lack of 
effect on cellular localization of total α5β1 (Figures 2B, S2A).  In contrast, silencing of RhoJ 
significantly increased the internalization of active α5β1 (Figure 2F).  In the assay, internalized 
active α5β1 will eventually resolve through the recycling and degradative pathways.  Silencing 
of RhoJ also increased amount of internalized active α5β1 present at later time points (Figure 
2F), suggesting that RhoJ also affects the subsequent onward trafficking of this complex. 
Recent work has shown that active α5β1 recycles via a TGN46+ compartment in ECs [20].  We 
examined the steady-state distribution of active α5β1 in ECs and found that loss of RhoJ 
significantly increased the pool of active α5β1 in TGN46+ recycling vesicles, with a parallel 
reduction in vesicles positive for the late endosomal/lysosomal marker LAMP1 (Figures 2G, 
S2E).  To examine this further, we performed recycling assays.  In these assays, the fate of a 
pool of internalized, biotinylated α5β1 is followed over time.  While silencing of RhoJ increased 
the presence of active α5β1 in the TGN46+ recycling compartment, it had no significant effect 
on the rate of return of active integrin to the cell surface (Figure 2H).  The rate of recycling of 
total α5β1 was not affected either (Figure 2H).   
 
We conclude that RhoJ suppresses an internalization pathway that carries active α5β1 to the 
TGN46+ recycling pathway.  In the absence of RhoJ, more active α5β1 heterodimers are 
internalized.  While the rate of return of active α5β1 is unaffected, the size of the internal pool is 
increased and so the amount of active α5β1 returned to the surface is greater.  Depletion of 
RhoJ also causes a shift in the localization of internalized active α5β1 away from the late 
endosomal compartment and towards the TGN46+ recycling compartment, suggesting that 
RhoJ may alter the route of trafficking also.  
 
α2β1 is an important collagen receptor in ECs [15].  As we identified α2 integrin in the RhoJ 
vesicle proteome (Figure 1D), we examined whether RhoJ also regulates trafficking of this 
integrin.  Depletion of RhoJ caused a small increase in the internalization of D2 integrin but did 
not affect its recycling rate (Figure S2F), or the distribution of D2 integrin between the surface 
and internal pools (Figure S2G).  Tools are not available to measure the trafficking of active 
α2β1 and so we cannot exclude a role for RhoJ in trafficking of the active α2β1 integrin. 
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RhoJ regulates the endothelial assembly of fibrillar fibronectin 
RhoJ has been shown to regulate the size and number of focal adhesions in ECs [3], 
suggesting a possible role for RhoJ in mediating EC adhesion.  Integrin α5β1 is the major 
receptor for fibronectin in ECs [21], so we compared adhesion to fibronectin with other ECM 
components.  Silencing of RhoJ had a small but significant inhibitory effect on EC adhesion, but 
not specifically to fibronectin (Figure S3A).  Similarly, activated RhoJ increased general 
adhesion to a small but significant degree (Figure S3A).  Integrin α5β1 is also critical for the 
remodeling of secreted soluble fibronectin into fibrillar fibronectin [22].  ECs assemble fibrillar 
fibronectin during angiogenesis and this temporary 3D matrix is required for vessel formation 
[23].  Fibronectin fibrillogenesis requires the internalization and recycling of active α5β1 integrin 
through the TGN46+ compartment [20, 24, 25], suggesting that active RhoJ might inhibit this 
process.  Indeed, silencing of RhoJ led to a dramatic increase in the assembly of fibronectin into 
fibrils that was apparent both visually (Figure 3A) and in the quantification of deoxycholate-
insoluble fibronectin fibrils (Figure 3B).  Conversely, expression of activated RhoJ suppressed 
fibronectin fibrillogenesis (Figures 3A, 3C).   Identical results were obtained with exogenously 
added, fluorescent fibronectin, demonstrating that this does not depend on fibronectin synthesis 
(Figure S3B).  Similarly, RhoJ did not affect the rate of secretion of fibronectin from ECs (Figure 
S3C), demonstrating that this effect was not due to a net increase in fibronectin production by 
the cells.  We conclude that RhoJ negatively regulates the assembly of soluble fibronectin into 
fibrils.  
 
RhoJ opposes Cdc42 in regulating fibronectin fibrillogenesis through competition for 
PAK3 
Recent work has shown that RhoJ and Cdc42 are reciprocally regulated in ECs.  Cdc42 is 
activated by the pro-angiogenic growth factor VEGF downstream of Arhgef15, whereas RhoJ is 
inactivated [26].  Conversely, the guidance molecule semaphorin 3E activates RhoJ in ECs 
during angiogenesis and inhibits Cdc42 [27].  This evidence for reciprocal regulation suggested 
that some functions of these Rho GTPases might be in opposition.  Accordingly, we found that 
silencing of Cdc42 (Figure S3D) significantly inhibited fibronectin fibrillogenesis (Figures 3D, 
3E), whereas activated Cdc42 promoted this process (Figures 3D, 3F).   
 
RhoJ is known to have an overlapping binding specificity with Cdc42 and to share partners such 
as WASP and PAK1 [11, 28].  To identify RhoJ/Cdc42 binding partners in ECs, we transduced 
cells with GFP-tagged, activated mutants of the two proteins and analyzed the complexes by 
tandem mass-tag mass spectrometry [29].  The majority of known Cdc42 interactors could also 
be found in RhoJ complexes (Figure 4D, Data S2).  Interestingly, RhoJ appeared to interact less 
well overall, and bound to some Cdc42 effectors better than others (Figure 4D).  Of the 
previously characterized Cdc42 interactors, RhoJ bound best to PAK3 in ECs (Figure 4D).  This 
interaction was confirmed by immunoprecipitation (Figure S3E).  In keeping with the mass 
spectrometry data, Cdc42 was more effective at immunoprecipitating PAK3, suggesting a higher 
binding efficiency (Figure S3E).  Silencing of PAK3 (Figure S3F) had no effect on the rate of 
internalization of active α5β1, but like RhoJ caused an increase in amount of internalized 
activated integrin in the cell at later timepoints (Figure S3I).  
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The effects of silencing of PAK3 on fibronectin fibrillogenesis phenocopied the effects of 
silencing of Cdc42, with significant loss of fibrillar fibronectin (Figures 4A, 4B).  Similarly, 
overexpression of PAK3 phenocopied Cdc42 activation, with promotion of fibrillogenesis 
(Figures 4A, 4C).  There was no change to the rate of fibronectin secretion (Figure S3H).  
Intriguingly, activated RhoJ was able to suppress the promotion of fibrillogenesis caused by 
PAK3 and, by corollary, PAK3 was able to partially rescue the inhibition of fibrillogenesis caused 
by activated RhoJ (Figure 4E, S3G).  We conclude that RhoJ negatively regulates fibronectin 
fibrillogenesis in ECs at least in part by competition with Cdc42 for PAK3.   
 
PAK3 is related to PAK1 and 3; collectively forming the Group I PAKs [30].  Silencing of PAK2 
did not affect fibrillogenesis; however, silencing of PAK1 did, although to a lesser degree than 
PAK3 (Figures S4A-C).  Interestingly, RhoJ has previously been shown to activate PAK1 and 
PAK3 in melanoma cells, but not PAK2 [31].  Treatment of ECs with the Group I PAK inhibitor 
FRAX486 had a greater effect than silencing either PAK alone (Figure S4D), suggesting that 
both PAK1 and PAK3 contribute to this process. 
 
RhoJ regulates fibronectin fibrillogenesis during angiogenesis 
To determine the role of RhoJ in fibronectin fibrillogenesis in vivo, we examined fibronectin 
deposition during developmental angiogenesis of the retina in RhoJ -/- mice.  RhoJ is highly 
expressed in the ECs of these vessels as they develop [4, 27] and loss of RhoJ causes a 
reduced rate of vessel outgrowth that is associated with destabilization of new capillaries at the 
vascular front [4].  At postnatal day 7, modest deposition of fibronectin was detected broadly 
over the developing retinal vasculature in wild-type mice (Figures 4F, S4E).  In contrast, loss of 
RhoJ led to a marked increase in fibronectin staining specifically at the vascular front, with the 
additional fibronectin wrapped around the actively forming vessels (Figures 4F, S4E).  We 
conclude that RhoJ functions in angiogenesis to control the deposition of the fibrillar fibronectin 
matrix, with a loss of this function leading to instability and regression of newly formed vessels 
due retention of this provisional matrix. 
 
Our work has uncovered a key role for RhoJ in the trafficking of active α5β1 integrin.  Active β1 
integrins are trafficked differently to inactive β1 integrins, with a higher internalization rate and 
sorting to the late endosomal compartment prior to recycling [32].  RhoJ acts to inhibit 
internalization of the active form of α5β1 specifically, leading to decreased flux through the cell.  
While RhoJ does not affect the rate of recycling of internalized, active α5β1, it appears to route 
it away from the TGN46+ compartment and towards the late endosomal compartment.  As 
traffic through the TGN46+ compartment is required for fibronectin fibrillogenesis [20], the net 
effect is to decrease the supply of active α5β1 for this process. 
 
ECs assemble fibrillar fibronectin during angiogenesis to provide a provisional proangiogenic 
matrix for vessel formation [23].  Conversely, fibrillogenesis must be switched off in mature 
vessels to promote stability and to avoid generation of pro-inflammatory, atherogenic signals.  
Our data support a model (Graphical Abstract) in which RhoJ suppresses fibronectin 
fibrillogenesis in quiescent ECs.  At the onset of angiogenesis, VEGF-mediated inactivation of 
RhoJ would then release this brake, allowing for deposition of the provisional fibronectin matrix.  
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RhoJ would then be reactivated at the end of vessel formation to allow its role in lumenogenesis 
[9].  Importantly, RhoJ reactivation would also suppress fibronectin deposition in the mature 
vessel, allowing for stability and a return to quiescence.  It is apparent that VEGF receptor 
signaling acts on integrin function in many ways in ECs [33, 34] and it will be important to 
explore the links between these pathways and RhoJ signaling in further detail. 
 
The discovery of reciprocal roles for RhoJ and Cdc42 in this process also gives insight into the 
functional consequences of the expansion of the Rho GTPase family.  We had expected to find 
unique RhoJ partners that would mediate the specific roles of RhoJ in the endothelium.  Instead 
we found that RhoJ interacts with a largely overlapping set of partners to Cdc42, albeit with a 
different order of preference.  RhoJ acts in opposition to its more ancient relative Cdc42, 
competing for their shared partner PAK3.  In this way, the reciprocal regulation of these two Rho 
GTPases during angiogenesis allows for reciprocal regulation of fibrillogenesis.  Similar gene 
duplications have occurred for Rac1 and RhoA, the two other archetypal Rho GTPases.  It will 
be important to determine if similar reciprocal regulatory mechanisms exist elsewhere in the 
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Figure 1. Endothelial RhoJ+ vesicles transport α5β1 integrin 
 
(A)  ECs were transfected with GFP-Cdc42 or GFP-RhoJ.  Cdc42 had a broad cytoplasmic 
distribution, whereas RhoJ was also seen in vesicles that colocalized with the early endosomal 
marker EEA1 (red).  Quantification of these vesicles showed substantial colocalization with 
EEA1 and with the late endosomal marker LAMP1 (Figure S1A), but not with the trans-Golgi 
marker TGN46.  Data are means ± SEM; n=10 cells.  Scale bar = 10μm. 
(B)  Post-nuclear supernatants from ECs transduced with GFP-RhoJ QL were subjected to 
density ultracentrifugation on 10-30% iodixanol gradients.  Fractions were analyzed by western 
blotting.  RhoJ was recovered in membranes co-sedimenting with the plasma membrane marker 
Na+/K+ ATPase, and with the early endosomal maker EEA1 and the late endosomal marker 
CD63.  Lesser amounts co-sedimented with the lysosomal marker LAMP2 or the endoplasmic 
reticulum marker calnexin.   
(C)  RhoJ+ endosomes from the density gradient (blue box; Panel B) were post-labelled with 
Calcein Violet and further purified by particle sorting.  Purified RhoJ+ vesicles were analyzed by 
mass spectrometry. 
(D)  The RhoJ+ vesicle proteome (see Data S1) was filtered for a 1% false discovery rate and 
manually annotated into functional categories.  The pie chart shows the major classes of 
proteins present.  The RhoJ+ vesicle proteome was enriched in metabolic enzymes, 
cytoskeletal proteins and trafficking proteins.  Transmembrane proteins were annotated as 
vesicle ‘cargo’, of which 45% were cell adhesion proteins.  The Table shows individual adhesion 
proteins and Rab GTPases identified in the proteome. 
(E)  ECs were transfected with GFP-RhoJ and co-stained for endogenous α5 and β1 integrins 
(red).  RhoJ+ vesicles colocalized with both α5β1 subunits.  Scale bar = 10μm. Data are means 
± SEM; n=10 cells. 
 
Figure 2. RhoJ regulates active integrin α5β1 trafficking 
(A)  ECs were transfected with two independent RhoJ siRNAs and the effectiveness of silencing 
determined by western blotting. 
(B)  The cellular distribution of α5 integrin was determined by immunofluorescence microscopy.  
Neither silencing of RhoJ, or expression of an active RhoJ QL mutant affected α5 integrin 
distribution (see also Figure S2A).  Scale bar = 10μm. 
(C)  The cellular distribution of active α5β1 was examined in ECs using the conformation-
specific SNAKA51 antibody.  Silencing of RhoJ significantly increased SNAKA51 staining 
intensity, whereas expression of the intensity activated RhoJ QL significantly reduced it.  Scale 
bar = 10μm.  The graphs present quantification of active α5β1 staining, relative to control cells.  
Data are means ± SEM; n=9 independent experiments.  *** P ≤ 0.001; ** P ≤ 0.01; * P ≤ 0.05. 
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(D)  ECs were treated ± RhoJ siRNA.  Total and active α5β1 integrin were isolated separately 
by immunoprecipitation and quantified by western blotting.  Silencing of RhoJ had no effect on 
total α5β1 integrin levels (see Figure S2B); however, quantification showed a significant 
increase in levels of active α5β1 (Data are means ± SEM; n=3 independent experiments).  * P ≤ 
0.05.   
(E)  ECs were transduced with RhoJ QL and total and active α5β1 integrin were isolated 
separately by immunoprecipitation and quantified by western blotting.  Expression of activated 
RhoJ had no effect on total α5β1 integrin levels (see Figure S2C); however, quantification 
showed a significant decrease in levels of active α5β1.  Data are means ± SEM; n=3 
independent experiments.  ** P ≤ 0.01. 
(F)  ECs were treated ± RhoJ siRNA.  After 72h, cells were surface biotinylated on ice and then 
allowed to internalize surface proteins at 37°C.  At each timepoint, the remaining surface 
biotinylation was removed by MesNa treatment, and the amount of internalized α5β1 integrin 
was determined by streptavidin capture of biotinylated proteins and ELISA with α5β1 integrin-
specific antibodies.  Silencing of RhoJ had no significant effect on the internalization of total 
α5β1 integrin, but significantly increased the rate of internalization of active α5β1.  At later 
timepoints, levels of internalized active α5β1 were preserved, suggesting there was also a 
change to onward trafficking.  Data are means ± SEM; n=3 independent experiments.  *** P ≤ 
0.001; ** P ≤ 0.01; * P ≤ 0.05. 
(G) ECs were treated ± RhoJ siRNA.  After 48h, the steady-state distribution active α5β1 
integrin was determined by confocal immunofluorescence microscopy (see Figure S2E).  
Quantification showed that silencing of RhoJ significantly decreased the amount of active α5β1 
integrin in LAMP1+ late endosomes/lysosomes and significantly increased the amount of active 
α5β1 integrin in TGN46+ vesicles, consistent with a switch towards recycling of the active 
integrin.  Data are means ± SEM; n=4 independent experiments, 5 cells in each 
condition/experiment.  **** P ≤ 0.0001; *** P ≤   0.001; ** P ≤ 0.01.  
(H) ECs were treated ± RhoJ siRNA.  After 72h, cells were surface biotinylated on ice and then 
allowed to internalize surface proteins at 37°C for 24min.  Biotin on the remaining non-
internalised receptors was then removed using MesNa on ice. The internalised pool was then 
chased over the time points indicated and the biotin from recycled receptors was again removed 
by reduction with MesNa on ice. The amount of internalised pool lost to the surface is 
represented as % of the initial internalised pool in each case. Silencing of RhoJ had no 
significant effect on the recycling rate for total or active integrin α5β1.  Data are means ± SEM; 
n=3 experiments. 
 
Figure 3: RhoJ regulates the endothelial assembly of fibrillar fibronectin 
 
(A)  ECs were treated ± RhoJ siRNA or transduced with RhoJ QL.  Fibronectin deposition was 
examined by staining cells with an EDA-fibronectin antibody to detect cell-secreted fibronectin 
specifically.  Scale bar = 10μm.  Silencing of RhoJ significantly increased fibronectin fiber 
density, quantified as detailed in the methods.  Conversely, expression of the activated RhoJ QL 
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mutant significantly decreased fiber density (means ± SEM; n≥4 independent experiments).  
See also Figure S3B.  ** P ≤ 0.01; * P ≤ 0.05. 
(B)  Fibronectin fibrillogenesis in ECs was quantified by isolating deoxycholate (DOC) insoluble 
fibronectin and western blotting.  Silencing of RhoJ significantly increased fibrillogenesis (means 
± SEM; n=3 independent experiments).  * P ≤ 0.05.  
(C)   ECs were transduced with RhoJ QL and fibronectin fibrillogenesis was quantified by 
isolating DOC-insoluble fibronectin and western blotting.  Expression of activated RhoJ 
significantly inhibited fibrillogenesis (means ± SEM; n=3 independent experiments).  ** P ≤ 0.01. 
(D)  ECs were treated ± Cdc42 siRNA or transduced with Cdc42 QL.  Fibronectin deposition 
was examined by staining cells with an EDA-fibronectin antibody to detect cell-secreted 
fibronectin specifically.  Scale bar = 10μm.  Silencing of Cdc42 significantly decreased 
fibronectin fiber density.  Conversely, expression of the activated Cdc42 QL mutant significantly 
increased fiber density (means ± SEM; n=4 independent experiments).  ** P ≤ 0.01; * P ≤ 0.05. 
(E)  Fibronectin fibrillogenesis in ECs was quantified by isolating deoxycholate (DOC) insoluble 
fibronectin and western blotting.  Silencing of Cdc42 (see Figure S3C) significantly decreased 
fibrillogenesis (means ± SEM; n=3 independent experiments).  * P ≤ 0.05.  
(F)   ECs were transduced with Cdc42 QL and fibronectin fibrillogenesis was quantified by 
isolating DOC-insoluble fibronectin and western blotting.  Expression of activated Cdc42 
significantly increased fibrillogenesis (means ± SEM; n=3 independent experiments).  * P ≤ 
0.05. 
 
Figure 4. RhoJ opposes Cdc42 in endothelial fibronectin fibrillogenesis through 
competition for PAK3 
 
(A)  ECs were treated ± PAK3 siRNA (see Figure S3F) or transduced with myc-tagged PAK3.  
Fibronectin deposition was examined by staining cells with an EDA-fibronectin antibody to 
detect cell-secreted fibronectin specifically.  Scale bar = 10μm.  Silencing of PAK3 significantly 
decreased fibronectin fiber density.  Conversely, overexpression of PAK3 significantly increased 
fiber density (means ± SEM; n=4 independent experiments).  *** P ≤ 0.001; * P ≤ 0.05. 
(B)  Fibronectin fibrillogenesis in ECs was quantified by isolating deoxycholate (DOC) insoluble 
fibronectin and western blotting.  Silencing of PAK3 significantly decreased fibrillogenesis 
(means ± SEM; n=3 independent experiments).  * P ≤ 0.05.  
(C)   ECs were transduced with myc-tagged PAK3 and fibronectin fibrillogenesis was quantified 
by isolating DOC-insoluble fibronectin and western blotting.  Conversely, overexpression of 
PAK3 significantly increased fibrillogenesis (means ± SEM; n=3 independent experiments).  * P 
≤ 0.05. 
(D)  ECs were transduced with either GFP, GFP-RhoJ QL or GFP-Cdc42 QL.  Binding partners 
of active RhoJ and Cdc42 were determined by GFP-Trap and TMT mass spectrometry (see 
Data S2).  The table shows the subset of previously identified Cdc42 binding partners and the 
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ratio of their abundance compared to the GFP control.  The abundance ratios of RhoJ 
compared to the GFP control are shown too.  RhoJ showed reduced binding to Cdc42 effectors 
such as SPEC2 and BORG2.  PAK3 was the shared effector with the highest binding to RhoJ. 
(E)  The ability of PAK3 to rescue RhoJ-mediated inhibition of fibrillogenesis was investigated by 
transducing ECs with combinations of the active RhoJ mutant and PAK3.  Fibronectin 
fibrillogenesis was assessed by quantifying DOC-insoluble fibronectin as before.  Fibrillogenesis 
was also examined by immunofluorescence microscopy (Figure S3G).  Expression of PAK3 
partially rescued the RhoJ-mediated suppression of fibrillogenesis.  By corollary, expression of 
RhoJ QL inhibited the promotion of fibrillogenesis by PAK3 (means ± SEM; n=3 independent 
experiments).  * P ≤ 0.05. 
(F)  Immunohistochemistry was performed on whole mount retina from littermate control 
RhoJWT/WT mice and the RhoJ null RhoJGFP/GFP mice on postnatal day 7 (P7). Staining was 
undertaken using rat anti-PECAM-1(red; to mark the retinal vessels) and mouse anti-EDA-
fibronectin antibodies (green; clone IST-9). The lower panel represents a zoomed in image of 





LEAD CONTACT AND MATERIALS AVAILABILITY 
 
Further information and requests for resources and reagents should be directed to and will be 
fulfilled by the Lead Contact, Harry Mellor (h.mellor@bristol.ac.uk).  All unique/stable reagents 
generated in this study are available from the Lead Contact without restriction. 
 
 
EXPERIMENTAL MODEL AND SUBJECT DETAILS 
Cell culture 
Primary human umbilical vein endothelial cells (HUVEC) from pooled donors were from Lonza 
and were cultured at 37°C in complete endothelial cell growth media (EGM-2; Lonza) without 
VEGF. Cells were used between passages 2-6.  Where indicated, HUVEC were transfected 
with siRNA oligonucleotides using GeneFECTOR lipid according to the manufacturer’s protocol 
(Venn Nova).  HEK 293T cells were cultured at 37°C in DMEM supplemented with 10% FBS, 
100U/ml penicillin and 100μg/ml streptomycin.  
 
Lentiviral transduction 
Experiments used the lentiviral expression vector pLVXpuro vector (Takara Bio).  Lentiviral 
particles were produced in a HEK293T packaging line, using standard methods.  Briefly, cells 
were transfected with pLVXpuro and the packaging vectors pMDG2 and pAX2, using 
lipofectamine.  After 48h, the culture supernatants were added to ECs for 6h. Cells were 
selected for stable expression in media supplemented with 2µg/ml puromycin. 
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RhoJ KO mice 
The generation of RhojGFP/GFP mice was described previously [5].  To obtain RhoJGFP/GFP mice 
and littermate control RhoJWT/WT mice, heterozygous RhojGFP/WT male and female with a C57BL/6 
background were intercrossed. Both males and females were included since no differences 
between sexes were observed.  Mice were healthy with normal immune status, were not subject 
to prior procedures, were fed with unlimited access to food and water, and were housed in 
specific pathogen-free condition. Animal care and all experimental procedures were performed 





ECs were fixed in 4% paraformaldehyde and permeabilized with 0.2% Triton X-100 or 0.1% 
saponin, as indicated. Confocal microscopy was performed using a Leica SP5 AOBS confocal 
laser-scanning microscope with an attached Leica DM I6000 inverted microscope. Confocal 
sections were taken across the z-plane and processed to form a 2D projection representing the 
full depth of the cell culture. 
 
Vesicle isolation and proteomics 
The protocol for vesicle enrichment and sorting was adapted from [35]. Briefly, ECs transduced 
with GFP-RhoJ QL were washed with ice-cold PBS and scraped into homogenization buffer 
(250mM sucrose, 8mM CaCl2, 4mM MgCl2, 78mM KCl, 10mM EGTA, 5mM HEPES, pH 7.2 with 
protease inhibitors). The cells were homogenized in a Balch homogenizer with a tungsten 
carbide ball bearing (10µm clearance). Homogenates were centrifuged for 5min at 1000 x g to 
remove the nuclei. The post-nuclear supernatant was loaded on top of a 10-30% iodixanol 
density gradient and ultracentrifugation was carried out for 18h at 4°C.  Endosomal fractions 
were post-labelled with Calcein Violet-AM [12] and sorted using a Becton Dickinson Influx high 
speed sorter custom configured for small particle detection and sorting.  Protein from 
GFP/Calcein double-positive vesicles was precipitated with TCA and the pellet was washed 
three times with ice-cold acetone and resuspended in SDS-PAGE sample buffer.  Samples 
were run approximately 1cm into the separating gel and the gel lane was then cut as a single 
gel slice and subjected to in-gel tryptic digestion.  The resulting peptides were fractionated using 
an Ultimate 3000 nanoHPLC system in line with an LTQ-Orbitrap Velos mass spectrometer 
(Thermo Scientific).  The raw data files were processed and quantified using Proteome 
Discoverer software v1.4 (Thermo Scientific) and searched against the UniProt Human 
database using the SEQUEST algorithm. Peptide precursor mass tolerance was set at 10ppm, 
and MS/MS tolerance was set at 0.8Da. Search criteria included carbamidomethylation of 
cysteine (+57.0214) as a fixed modification and oxidation of methionine (+15.9949) as a 
variable modification. Searches were performed with full tryptic digestion and a maximum of 1 
missed cleavage was allowed. The reverse database search option was enabled, and all 






ECs were washed with ice-cold PBS and harvested in lysis buffer (20 mM Tris pH7.5, 137 mM 
NaCl, 0.5% NP-40, 2mM sodium orthovanadate, 10mM sodium fluoride) containing protease 
inhibitor cocktail. Cell lysates were centrifuged for 12min at 12,000 x g at 4ºC.  The clarified 
supernatants were incubated with the relevant antibodies for 30min and the complexes captured 
by subsequent incubation for 2h with Protein G Sepharose beads (Sigma-Aldrich).  The beads 
were washed 3 times in lysis buffer and the immunoprecipitated proteins were then extracted 
from the beads by heating at 95°C with SDS-PAGE sample buffer, prior to analysis by western 
blotting.  For immunoprecipitation of GFP-tagged proteins, lysates were incubated directly with 
GFP-Trap A beads (ChromoTek). 
 
Cell adhesion assays 
96 well cell culture plates were coated with either BSA (3%), fibronectin (2µg/ml), collagen I (2 
µg/ml) or purified basement membrane (10% Geltrex). 6000 ECs were seeded per well and 
allowed to adhere for 15min. The unattached cells were removed with PBS.  Attached cells 
were fixed with glutaraldehyde, stained with DAPI and counted using the Incucyte automated 
imaging system (Sartorius). 
 
Quantification of fibronectin fibrillogenesis 
Fibronectin fibrillogenesis was quantified by immunofluorescence microscopy and analysis of 
DOC-insoluble fibronectin.  For quantification by immunofluorescence microscopy, 1 x 105 
HUVEC cells were plated on coverslips in a 12-well plate.  After 24h, cells were fixed with 4% 
PFA and stained for EDA-fibronectin.  Images were acquired using a 40x oil lens on a Leica 
DMI6000 inverted epifluorescence microscope. 15 random fields were acquired per condition. 
Fibers were identified using ImageJ with the Ridge Detection plugin with width estimation 
enabled. Fibril density (pixels positive for objects identified as fibres) was calculated using a 
custom macro.  Alternatively, ECs were incubated with 2.5µg/ml soluble rhodamine fibronectin 
(Cytoskeleton Inc) for 30min at 37ºC followed by fixation. The rhodamine fibronectin 
incorporated into fibrillar structures was imaged by widefield microscopy and the intensity of 
staining was quantified using ImageJ.  Quantification of deoxycholate-insoluble fibronectin was 
performed as previously described [25][25][25][25]. Briefly, 2x105 ECs were plated in 6-well 
tissue culture dishes and cultured for 24h. Cells were washed with ice-cold PBS and lysed in 
500µl of lysis buffer (20mM Tris, pH 8.5, 1% sodium deoxycholate, 2mM iodoacetamide, 2mM 
EDTA and protease inhibitors). Lysates were centrifuged at 20,000 x g for 30min to sediment 
the DOC-insoluble material. The resulting pellets were then washed twice more with lysis buffer 
and analyzed by western blotting.  
To quantify secreted fibronectin, ECs were washed and incubated with fresh, serum free EGM-2 
for 24 h.  After media collection, the samples were diluted 10-fold to measure fibronectin 
concentrations within the linear range, using a Quantikine ELISA kit (R&D Systems) according 
to manufacturer’s instructions. The amount of secreted fibronectin was calculated from a 





Integrin internalization assays 
Integrin internalization assays were adapted from [36].  Briefly, ECs were grown to confluency, 
washed twice with cold PBS, and surface-labelled on ice with 0.2mg/ml cleavable biotin (NHS-
SS-biotin; Pierce) in serum-free DMEM for 30min. Cells were then transferred to 37ºC to allow 
for internalization of surface-labelled proteins. At each time point, cells were returned to ice, 
washed twice with cold PBS and biotin was removed from proteins remaining at the surface 
using the reducing agent, MesNa (2.9mg/ml for 30min at 4oC). Free sulfhydryl groups were 
alkylated with iodoacetamide to prevent further biotinylation. The amount of internalized 
biotinylated integrin α5β1 and active α5β1 were measured by capture-ELISA using Maxisorp 
(Nunc) plates coated with monoclonal antibodies recognizing total α5β1 or active α5β1 
heterodimer (SNAKA51).  
 
Integrin recycling assays 
Integrin recycling assays were adapted from [36]. Briefly, following surface labeling with 
cleavable biotin, cells were transferred to serum-free DMEM for 30min at 37ºC to allow 
internalization. Cells were then washed twice with ice-cold PBS, and biotin was removed from 
proteins remaining at the cell surface using reduction with MesNa. The internalized fraction was 
then chased by returning the cells to 37°C in serum-free DMEM for the time points indicated. At 
each time point, the cells were returned to ice and biotin label was removed by a second round 
of MesNa treatment. The remaining biotinylated, internal integrin was quantified by capture 
ELISA. 
 
Surface biotinylation assay 
ECs were transfected with siRNAs, as before.  After 48h, the cells were washed twice with ice-
cold PBS, and surface-labelled on ice with 0.2mg/ml non-cleavable biotin (Sulfo-NHS-LC-Biotin, 
Pierce) for 30min. Cells were washed in ice-cold PBS, lysed and the biotinylated proteins 
captured on streptavidin agarose beads. The unbound fraction (the internal pool) and the 
captured fraction (surface pool) were evaluated by immunoblotting. 
 
TMT mass spectrometry 
ECs were transduced with GFP, GFP-RhoJ QL or GFP Cdc42 QL.  Each condition used two 
confluent 10cm tissue culture dishes.  GFP-tagged proteins were isolated from cell lysates using 
GFP-Trap A beads, as before.  After the washes, the immunoprecipitated samples were 
reduced (10mM TCEP 55°C, 1h), alkylated (18.75mM iodoacetamide, room temperature, 
30min) and digested on the beads with trypsin (2.5µg trypsin; 37°C, overnight), then labelled 
with Tandem Mass Tag (TMT) six plex reagents according to the manufacturer’s protocol 
(ThermoFisher Scientific).  The labelled samples were pooled prior to analysis by nano-LC 
MSMS using an Orbitrap Fusion Tribrid Mass Spectrometer.  The raw data files were processed 
and quantified using Proteome Discoverer software v2.1 (Thermo Scientific) and searched 
against the UniProt Human database using the SEQUEST algorithm. Peptide precursor mass 
tolerance was set at 10ppm, and MS/MS tolerance was set at 0.6Da. Search criteria included 
oxidation of methionine (+15.9949) as a variable modification and carbamidomethylation of 
cysteine (+57.0214) and the addition of the TMT mass tag (+229.163) to peptide N-termini and 
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lysine as fixed modifications. Searches were performed with full tryptic digestion and a 
maximum of 2 missed cleavages were allowed. The reverse database search option was 
enabled, and all data were filtered to satisfy a false discovery rate of 5%. 
 
Immunohistochemistry 
The procedures for preparations of retinal samples have been described previously [37].  The 
primary antibodies were rat anti-CD31 (1:500, Mec13.3, BD Biosciences), and mouse anti-
fibronectin (1:200, IST-9, Santa Cruz Biotechnology). Signals were detected with donkey IgGs 
conjugated with Alexa Fluor 568 or Alexa Fluor 647 (Life Technologies). Images of a retinal 
quadrant were taken with an LSM710 confocal microscope and combined using photomerge 
utility of Photoshop CS5 Extended software (version 12.0, Adobe).  
 
QUANTIFICATION AND STATISTICAL ANALYSIS 
 
Statistical analysis was performed using Graphpad Prism software.  One-sample t-test was 
used to compare fold changes against the normalized control in experiments comparing 2 
samples. In experiments with 3 or more samples with a single independent variable, one-way 
repeat measures ANOVA (block ANOVA) was used followed by Dunnett’s multiple comparisons 
test. In experiments with 2 independent variables (Figures 2F, G), two-way repeat measures 
ANOVA (block ANOVA) was used followed by Bonferroni’s multiple comparisons test. *** P ≤ 
0.001; ** P ≤ 0.01; * P ≤ 0.05. 
 
DATA AND CODE AVAILABILITY 
 
Custom macros for fibronectin fibrillogenesis analysis are freely available from the sources 




SUPPLEMENTARY DATA LEGENDS 
 
Data S1.  RhoJ vesicle proteomics, related to Figure 1 
RhoJ+ vesicles were purified by fluorescence activated vesicle sorting (FAVS) and mass 
spectrometry as described in STAR methods. The proteome was analyzed in Proteome 
Discoverer v1.4 and those satisfying 1% False Detection Rate cut off are represented in the 
Excel file. Column A, (Accession) is the unique identifier assigned to the protein by the FASTA 
database. Column B (Description) is the name of the protein. Column C (Score) is the protein 
score which is the sum of all scores for individual peptides. A score for a peptide is the sum of 
Xcorr values above the specified threshold. The score threshold is calculated as follows: 0.8 + 
peptide_charge × peptide_relevance_factor where peptide_relevance_factor is used at a default 
value of 0.4. For each spectrum, only the highest-scoring match is used. Column D (Coverage) 
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is the percentage of protein sequence covered by the identified peptides. Column E (#Unique 
peptides) displays the number of peptides unique to the protein group. Column F (#Peptides) 
displays the number of distinct peptide sequences in the protein group. Column G (#PSMs) 
displays the total number of identified peptide sequences (peptide spectrum matches) for the 
protein, including those redundantly identified. Column H (Area) displays the average area of 
the three unique peptides with the largest peak area.  
 
Data S2.  Comparative interactomes of RhoJ and Cdc42, related to Figure 4 
GFP Trap Immunoprecipitation followed by TMT Mass spectrometry was performed as 
described in the STAR methods. The Excel file shows the proteins identified at 5% False 
discovery rate (FDR).  Abundances are a measure of the reporter ions generated from the 
tandem mass tags at MS3.  The raw abundance values for the 3 conditions GFP control, GFP 
RhoJ-QL and GFP Cdc42-QL IPs are represented (columns C to E). The raw abundances are 
normalized to the GFP abundances in each case to obtain interactor abundances normalized to 
the amount of RhoJ and Cdc42 immunoprecipitated (column F to H).  The RhoJ-QL/GFP control 
and Cdc42-QL/GFP control values represent the fold enrichment of the interacting protein over 
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KEY RESOURCES TABLE 
REAGENT or RESOURCE SOURCE IDENTIFIER 
Antibodies   
Mouse monoclonal anti-
RhoJ 
Abnova Cat# H00057381-M01; 
RRID:AB_426036 
Rabbit monoclonal anti- 
Na+/K+ ATPase α1 (D4Y7E) 




Cell Signaling Technologies Cat# 3288; 
RRID:AB_2096811 
Goat polyclonal anti-CD63 Santa Cruz Biotechnology Cat# sc-7080; 
RRID:AB_648167 
Rabbit anti-LAMP-1 (270c)  gift from Prof. Ash Toye NA 
Rabbit polyclonal anti-
LAMP2  




BD Biosciences Cat# 610523; 
RRID:AB_397883 
Mouse monoclonal anti-
integrin α5 (CD49e) 
BD Biosciences Cat# 610633; 
RRID:AB_397963 
Mouse monoclonal anti-
integrin α5β1 (Clone VC5) 








R&D Systems Cat# BBA7, 
RRID:AB_356960 
Mouse monoclonal anti- α-
tubulin, ascites fluid, clone 
B-5-1-2 
Sigma Aldrich Cat#T5168; 
RRID:AB_477579 
Mouse monoclonal anti-
active integrin α5β1 
(SNAKA51) 
Novus Biologicals Cat# NBP250146 
Sheep polyclonal anti-
TGN46 
Serotec Cat# AHP500GT, 
RRID:AB_2203291 
Mouse monoclonal anti-
fibronectin (IST-9).  Raised 
Santa Cruz Biotechnology Cat# sc-59826, 
RRID:AB_783389 
Key Resource Table
against the EDA domain of 
fibronectin 
Mouse monoclonal anti-
fibronectin (FN-3E2).  
Raised against the EDA 
domain of fibronectin 
Sigma Aldrich Cat# 6140 
Rabbit polyclonal anti-
fibronectin 








BD Biosciences Cat# 610928, 
RRID:AB_398243 
Rabbit polyclonal anti-PAK3 Cell Signaling Technologies Cat# 2609, 
RRID:AB_2225298 
Rabbit polyclonal anti-GFP Cell Signaling Technologies Cat# 2555, 
RRID:AB_10692764 
Mouse monoclonal anti- 
myc-epitope tag (9E10) 
Santa Cruz Biotechnology Cat# sc-40, 
RRID:AB_627268 
Chemicals, Peptides, and 
Recombinant Proteins 
  
FRAX 486 R&D Systems Cat# 5190 
Rhodamine-fibronectin Cytoskeleton, Inc Cat# FNR01-A 
Fibronectin Sigma Aldrich Cat# F0895 
Collagen I Advanced Biomatrix Cat# 5409 
GFP-trap agarose beads Chromotek Cat# gta-20 
Myc-trap agarose beads Chromotek Cat# yta-20 
EZ-Link Sulfo NHS-LC-
Biotin 
Thermo Fisher Cat# 21335 
Sulfo-NHS-SS-Biotin Thermo Fisher  Cat# PG82077 
Human Fibronectin 
Quantkine ELISA kit 
R&D Biosystems Cat# DFBN10 
Experimental Models: Cell 
Lines 
  
Human umbilical vein 
endothelial cells (HUVEC) 
from pooled donors 




RhoJ WT mice  Generated in [5] C57BL/6 background 
RhojGFP/GFP GFP knock-in 
null mice 
Generated in [5] C57BL/6 background 
Oligonucleotides   
Mission siRNA Universal 
Negative Control 
Sigma Aldrich Cat#SIC001-5X1NMOL 




Dharmacon MU-003614-00- 0002 
(siGenome Set of 4) 




Dharmacon MU-003614-00- 0002 
(siGenome Set of 4) 




This paper Eurofins  




This paper Eurofins  




This paper Eurofins  




This paper Eurofins  
Recombinant DNA   
Plasmid pEGFP-Cdc42 
Cdc42 with N-terminal GFP 
tag 
This paper NA 
Plasmid pEGFP-RhoJ 
RhoJ with N-terminal GFP 
tag 
This paper NA 
Plasmid pEGFP Cdc42-QL 
Constitutively-active Cdc42 
(Q61>L) with N-terminal 
GFP tag 
This paper NA 
Plasmid pEGFP RhoJ QL 
Constitutively-active RhoJ 
(Q79>L) with N-terminal 
GFP tag 
This paper NA 
pLVx-puro GFP Cdc42QL  
Lentiviral expression vector 
encoding constitutively-
active Cdc42 
This paper NA 
pLVx puro GFP RhoJ-QL 
Lentiviral expression vector 
encoding constitutively-
active RhoJ 
This paper NA 
pLVx puro Myc PAK3  
Lentiviral expression vector 
encoding myc-tagged PAK3  
This paper NA 
Software and Algorithms   
Proteome Discoverer 2.1 Thermo Scientific manufacturer 
ImageJ [35] https://imagej.nih.gov/ij/ 
MIA workflow plugin This paper https://github.com/SJCross/
MIA/tree/v0.9.22 












































































B2R627 α5 integrin 63.17
B2R642 MCAM 58.65
P05556 β1 integrin 41.41
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Supplemental Figures and Legends
Figure S1. Endothelial RhoJ+ vesicles transport α5β1 integrin, related to Figure 1 
 
(A)  ECs were transfected with GFP-RhoJ.  RhoJ was seen in vesicles that colocalized with 
EEA1 (Figure 1A) and with the late endosomal marker LAMP1 (red).  Quantification is shown in 
Figure 1A.  Scale bar = 10μm. 
 
(B) ECs were transfected with GFP-RhoJ and co-stained for endogenous PECAM, VE-cadherin 
or integrin α2 (red).  In each case, a subset of vesicles was positive for RhoJ (red arrowheads).  
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Figure S2. RhoJ regulates active integrin α5β1 trafficking, related to Figure 2 
(A)  ECs were transfected with RhoJ siRNA or transduced with wild-type RhoJ (GFP-RhoJ-WT) 
or GFP-RhoJ-QL.  Postnuclear supernatants (PNS) were subjected to density gradient 
ultracentrifugation on 10-30% iodixanol gradients.  The cellular distribution of α5 integrin was 
analyzed by western blotting.  Neither silencing of RhoJ, or expression of the wild type or 
activated RhoJ affected α5 integrin distribution. 
 
(B)  ECs were treated ± RhoJ siRNA and total α5 integrin was quantified by western blotting.  
Data are means ± SEM; n=3 independent experiments. Silencing of RhoJ had no effect on total 
α5 integrin levels.  
(C)  ECs were transduced with activated RhoJ and total α5 integrin was quantified by western 
blotting.  Data are means ± SEM; n=3 independent experiments. Expression of activated RhoJ 
had no effect on total α5 integrin levels.  
(D)  ECs were treated ± RhoJ siRNA and cells were fixed and permeabilized with saponin to 
selectively reveal SNAKA51+ vesicles.  The number of SNAKA51+ vesicles per cell was 
increased significantly on silencing of RhoJ.  Data are means ± SEM; n=6 independent 
experiments, with 5 cells quantified per experiment for each condition.  
(E)  ECs were treated ± RhoJ siRNA.  After 48h, the steady-state distribution of active α5β1 
integrin was determined by confocal immunofluorescence microscopy. Representative confocal 
images with active α5β1 in green and the compartment markers LAMP1 and TGN46 (red) are 
shown. Arrows indicate colocalization.  Silencing of RhoJ decreased colocalization of active 
α5β1 with LAMP1+ vesicles and increased colocalization with TGN46+ vesicles (see Figure 
2G).  Scale bar = 2μm. 
(F)  ECs were treated ± RhoJ siRNA. After 72h, cells were surface biotinylated on ice and then 
allowed to internalize surface proteins at 37°C for 24min. Biotin on the remaining non-
internalized receptors was then removed using MesNa on ice.  The amount of internalized α2 
integrin is shown as a percentage of the initial surface pool.  Silencing of RhoJ caused a small 
but significant increase in the rate of internalization of α2 integrin.  The internalized pool was 
then chased over the time points indicated and the biotin from recycled receptors was again 
removed by reduction with MesNa on ice. The amount of internalized pool lost to the surface is 
represented as % of the initial internalized pool in each case. Silencing of RhoJ had no 
significant effect on the recycling rate for total α2β1. Data are means ± SEM; n=3 experiments.  
* P ≤ 0.05. 
(G)  ECs were treated ± RhoJ siRNA.  After 48h, surface proteins were biotinylated on ice.  The 
cells lysates were incubated with streptavidin beads to capture surface proteins and the 
unbound fraction was taken as the internal pool.  The surface and internal pools of α2 integrin 
were then examined by western blotting.  There was no apparent effect of RhoJ depletion on 


























































































































































































































































Figure S3. RhoJ regulates the endothelial assembly of fibrillar fibronectin, related to 
Figure 3 
(A)  ECs were treated ± RhoJ siRNA or transduced with activated RhoJ-QL.  Cells were plated 
in triplicate onto the indicted ECM components or a BSA control.  After 15min, adherent cells 
were then fixed and counted. Cells depleted of RhoJ showed a small but significant decrease in 
adhesion to all ECM components.  Cells expressing activated RhoJ showed a small but 
significant increase in adhesion to all ECM components.  Data are means ± SEM; n=6 
independent experiments).  * P ≤ 0.05. 
 
(B)  ECs were treated ± RhoJ siRNA or transduced with activated RhoJ-QL and then incubated 
with 2.5 µg/ml rhodamine fibronectin for 30min.  Scale bar = 10μm. The intensity of signal per 
cell was quantified from 10 random widefield images per condition. Silencing of RhoJ 
significantly increased the deposition of fibronectin.  Expression of activated RhoJ decreased 
fibronectin deposition.  Data are means ± SEM; n=5 independent experiments.  ** P ≤ 0.01; * P 
≤ 0.05. 
 
(C)  ECs were transfected with siRNA targeting RhoJ or transduced with activated RhoJ-QL. 
Cell medium was conditioned for 24h and the amount of fibronectin secreted by cells was 
determined by ELISA.  Depletion of RhoJ had no effect on fibronectin secretion.  Data are 
means ± SEM; n=3 independent experiments.   
 
(D)  ECs were transfected with two independent siRNAs targeting Cdc42 and the effectiveness 
of silencing determined by western blotting. 
 
(E) HEK 293T cells were transiently transfected with combinations of PAK3, RhoJ-QL and 
Cdc42-QL, as indicated.  Cdc42 and RhoJ were isolated by GFP-Trap immunoprecipitation and 
the coimmunoprecipitation of PAK3 was determined by western blotting.   Both RhoJ and Cdc42 
interacted with PAK3; however, the association of PAK3 with activated Cdc42 was greater. 
 
(F)  ECs were transfected with two independent siRNAs targeting PAK3 and the effectiveness of 
silencing determined by western blotting. 
 
(G)  The ability of PAK3 to rescue RhoJ-mediated inhibition of fibrillogenesis was investigated 
by transducing ECs with combinations of the active RhoJ mutant and PAK3.  Expression of 
PAK3 partially rescued the RhoJ-mediated suppression of fibrillogenesis.  By corollary, 
expression of RhoJ QL inhibited the promotion of fibrillogenesis by PAK3.  Fibronectin 
fibrillogenesis was assessed by quantifying DOC-insoluble fibronectin (Figure 4E). 
 
(H) ECs were transfected with siRNAs targeting PAK3 or a control.  Cell medium was 
conditioned for 24h and the amount of fibronectin secreted by cells was determined by ELISA.  
Depletion of PAK3 had no effect on fibronectin secretion.  Data are means ± SEM; n=3 
independent experiments.   
 
(I)  ECs were treated ± PAK3 siRNA.  After 72h, cells were surface biotinylated on ice and then 
allowed to internalize surface proteins at 37°C.  At each timepoint, the remaining surface 
biotinylation was removed by MesNa treatment, and the amount of internalized active α5β1 
integrin was determined by streptavidin capture of biotinylated proteins and ELISA with specific 
antibodies.  Silencing of PAK3 had no significant effect on the internalization of total α5β1 
integrin, but significantly increased lifetime of the internalized integrin.  Data are means  SEM; 



































































































































































Figure S4.  RhoJ opposes Cdc42 in endothelial fibronectin fibrillogenesis through 
competition for PAK3, related to Figure 4 
 
(A)  ECs transfected with siRNAs targeting PAK1 and PAK2 and their ability to silence 
expression of the proteins was assessed after 48h by western blotting.  
 
(B)  Fibronectin fibrillogenesis in ECs was quantified by isolating deoxycholate (DOC) insoluble 
fibronectin and western blotting.  Silencing of PAK1 significantly decreased fibrillogenesis while 
PAK2 had no effect.  Data are means  SEM; n=3 independent experiments.  * P  0.05. 
 
(C)  ECs were treated ± siRNA targeting PAK1 or PAK2.  Fibronectin deposition was examined 
by staining cells with an EDA-fibronectin antibody to detect cell-secreted fibronectin specifically.  
Silencing of PAK2 had no apparent effect on fibronectin fibrillogenesis; however, silencing of 
PAK1 dramatically reduced fibril formation 
 
(D)  ECs were treated with the Group I PAK inhibitor, FRAX486 at the concentrations indicated.  
Fibronectin fibrillogenesis was quantified by isolating deoxycholate (DOC) insoluble fibronectin 
and western blotting.  The effects of treatment with 500 nM FRAX486 were quantified.  Inhibition 
of Group I PAKs reduced fibronectin fibrillogenesis by 50%.  Data are means  SEM; n=3 
independent experiments.  * P ≤ 0.05. 
(E)  Immunohistochemistry was performed on whole mount retina from littermate control 
RhoJWT/WT mice and the RhoJ null RhoJGFP/GFP mice on postnatal day 7 (P7). Staining was 
undertaken using rat anti-PECAM-1(red; to mark the retinal vessels) and mouse anti-EDA-
fibronectin antibodies (green; clone 3E2). The lower panel represents a zoomed in image of the 
angiogenic front.  See also Figure 4F.  Scale bars:  Top panel = 200μm; bottom panel = 20μm. 
 
